Jardiance: the latest SGLT2 for the treatment of type 2 diabetes

Empagliflozin (Jardiance) is the third SGLT2 inhibitor available for the treatment of type 2 diabetes. Here we present the clinical data relating to its efficacy and adverse events.

Jardiance the latest SGLT2 for the treatment of type 2 diabetes

Add yours ↓
Web design and marketing agency Leamington Spa